Petra Moerer
Overview
Explore the profile of Petra Moerer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
1122
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Krohn S, Holtrop T, Brandsma A, Moerer P, Nederend M, Darzentas N, et al.
Viruses
. 2024 Apr;
16(4).
PMID: 38675937
Antibodies that specifically bind to individual human fragment crystallizable γ receptors (FcγRs) are of interest as research tools in studying immune cell functions, as well as components in bispecific antibodies...
2.
von Richthofen H, Westerlaken G, Gollnast D, Besteman S, Delemarre E, Rodenburg K, et al.
J Immunol
. 2023 Jan;
210(4):389-397.
PMID: 36637221
Signal inhibitory receptor on leukocytes-1 (SIRL-1) is an immune inhibitory receptor expressed on human granulocytes and monocytes that dampens antimicrobial functions. We previously showed that sputum neutrophils from infants with...
3.
Evers M, Ten Broeke T, Jansen J, Nederend M, Hamdan F, Reiding K, et al.
MAbs
. 2020 Aug;
12(1):1795505.
PMID: 32744145
Current combination therapies elicit high response rates in B cell malignancies, often using CD20 antibodies as the backbone of therapy. However, many patients eventually relapse or develop progressive disease. Therefore,...
4.
Meyer S, Evers M, Jansen J, Buijs J, Broek B, Reitsma S, et al.
Br J Haematol
. 2018 Feb;
180(6):808-820.
PMID: 29468712
Based on their mechanisms-of-action, CD20 monoclonal antibodies (mAbs) are grouped into Type I [complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC)] and Type II [programmed cell death (PCD) and ADCC]...
5.
Groen R, Noort W, Raymakers R, Prins H, Aalders L, Hofhuis F, et al.
Blood
. 2012 Jun;
120(3):e9-e16.
PMID: 22653974
Interactions within the hematopoietic niche in the BM microenvironment are essential for maintenance of the stem cell pool. In addition, this niche is thought to serve as a sanctuary site...
6.
Roodhart J, Daenen L, Stigter E, Prins H, Gerrits J, Houthuijzen J, et al.
Cancer Cell
. 2011 Sep;
20(3):370-83.
PMID: 21907927
The development of resistance to chemotherapy is a major obstacle for lasting effective treatment of cancer. Here, we demonstrate that endogenous mesenchymal stem cells (MSCs) become activated during treatment with...
7.
van Meerten T, Rozemuller H, Hol S, Moerer P, Zwart M, Hagenbeek A, et al.
Haematologica
. 2010 Sep;
95(12):2063-71.
PMID: 20851867
Background: Incorporation of the chimeric CD20 monoclonal antibody rituximab in the treatment schedule of patients with non-Hodgkin's lymphoma has significantly improved outcome. Despite this success, about half of the patients...
8.
van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A, et al.
Cell
. 2002 Nov;
111(2):241-50.
PMID: 12408868
The transactivation of TCF target genes induced by Wnt pathway mutations constitutes the primary transforming event in colorectal cancer (CRC). We show that disruption of beta-catenin/TCF-4 activity in CRC cells...